SCM
BIO icon

Stevens Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Stevens Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-516
Closed -$215K – 128
2022
Q3 		$215K Buy
+516
New +$257K 0.14% 123
2022
Q2 		– Sell
-835
Closed -$470K – 136
2022
Q1 		$470K Buy
835
+497
+147% +$300K 0.1% 172
2021
Q4 		$255K Buy
+338
New +$253K 0.06% 217
2019
Q4 		– Sell
-1,744
Closed -$580K – 606
2019
Q3 		$580K Sell
1,744
-14,341
-89% -$4.68M 0.05% 326
2019
Q2 		$5.03M Buy
16,085
+2,859
+22% +$856K 0.22% 134
2019
Q1 		$4.04M Buy
13,226
+9,595
+264% +$2.59M 0.17% 163
2018
Q4 		$843K Sell
3,631
-13,262
-79% -$3.56M 0.04% 410
2018
Q3 		$5.29M Buy
16,893
+6,505
+63% +$2.02M 0.19% 150
2018
Q2 		$3M Buy
10,388
+2,733
+36% +$755K 0.11% 222
2018
Q1 		$1.91M Buy
7,655
+1,795
+31% +$457K 0.07% 299
2017
Q4 		$1.4M Buy
+5,860
New +$1.42M 0.05% 364
2017
Q3 		– Sell
-3,272
Closed -$740K – 852
2017
Q2 		$740K Sell
3,272
-11,259
-77% -$2.45M 0.03% 494
2017
Q1 		$2.9M Buy
14,531
+7,602
+110% +$1.46M 0.11% 252
2016
Q4 		$1.26M Buy
6,929
+4,345
+168% +$741K 0.05% 391
2016
Q3 		$423K Buy
+2,584
New +$392K 0.02% 603
2016
Q1 		– Sell
-14,379
Closed -$1.99M – 895
2015
Q4 		$1.99M Buy
14,379
+8,803
+158% +$1.22M 0.08% 284
2015
Q3 		$749K Buy
5,576
+3,172
+132% +$457K 0.03% 421
2015
Q2 		$362K Sell
2,404
-4,490
-65% -$642K 0.01% 695
2015
Q1 		$932K Buy
6,894
+1,092
+19% +$135K 0.03% 429
2014
Q4 		$699K Buy
5,802
+1,050
+22% +$121K 0.02% 499
2014
Q3 		$539K Buy
+4,752
New +$563K 0.02% 572
2013
Q4 		– Sell
-9,582
Closed -$1.13M – 1014
2013
Q3 		$1.13M Buy
9,582
+3,030
+46% +$357K 0.03% 460
2013
Q2 		$735K Buy
+6,552
New +$769K 0.02% 499

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Stevens Capital Management's BIO Position: Q4 2022 in Review

Stevens Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2022, closing a stake of 516 shares — an estimated $215K sold.

Stevens Capital Management first reported a position in BIO in Q2 2013 and held it in 23 quarters. The position peaked at $5.29M in Q3 2018. 470 funds tracked by Wall St. Rank hold BIO as of Q4 2022.

  • Stevens Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2022 after selling out during the quarter.
  • Stevens Capital Management sold 516 Bio-Rad Laboratories Class A shares in Q4 2022, an estimated $215K.
  • Stevens Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 23 quarters.
  • Stevens Capital Management's Bio-Rad Laboratories Class A position peaked at $5.29M in Q3 2018.
  • 470 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2022.

Based on Stevens Capital Management's 13F filing for Q4 2022, filed 6 Feb 2023.